April 1, 2019
AstraZeneca and Daiichi Sankyo Sign $6.9 Billion Deal for a Single Cancer Drug | BioSpace
AstraZeneca signed a global development and commercialization deal with Daiichi Sankyo for trastuzumab deruxtecan (DS-8201),…